A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. Abstract Text:
The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or group B. Group A patients received 800 mg/d 5'-DFUR (Furtulon) for 2 years from 2 weeks after the operation. Group B patients received OK-432 plus 5'-DFUR by the same regimen as in group A. This study enrolled 288 patients, and 1 patient with malignant lymphoma was excluded. Among the remaining 287 patients, 143 and 144 were allocated to group A and group B, respectively, and their data were included in statistical analysis. The 5-year survival rates for groups A and B were 62.9% and 63.8%, respectively, showing no significant difference (P = 0.7996).
A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. Publishing Authors By Initials
A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. Journal Published:
PUBLICATION TYPE: Randomized Controlled Trial
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
VOLUME: 27
Page Numbers: 394-7
Journal Abbreviation: J. Immunother.
ISSN: 1524-9557
DAY: 18
MONTH: 03
YEAR: 2008
A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 9706083
A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. Keywords Mesh Terms:
KEYWORDS: Survival Analysis
MESH TERMS: mortality
Chemical & Substance for Abstract: A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. Information
Substance Name: Floxuridine
Registry Number: 50-91-9
Grant and Affiliation Information for A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer.
AFFILIATION: First Department of Surgery, School of Medicine, Hokkaido University, Sapporo, Japan. yuchan@med.hokudai.ac.jp
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: J Immunother
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer Related Publications